Skip to main content
    S

    STAAR Surgical Company (STAA)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $26.01
    -0.38 (-1.44%)

    Market Cap: $1.32B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    STAAR Surgical Company (STAA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    STAAR Surgical Company reported revenue of $239.44M for the fiscal year ended Dec 31, 2025, down 23.7% from the year before. That year, net income was -$80.45M with a net margin of -33.6%, operating cash flow was -$34.23M and free cash flow was -$40.05M. The quarter ended Sep 30, 2026 had revenue of $83.41M and net income of $5.58M.

    Revenue and Margins

    The operating margin was -38.3% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $82.43M, a compound annual rate of 12.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$239.44M-23.7%76.2%-38.3%-33.6%
    Dec 2024$313.90M-2.6%76.3%-4.0%-6.4%
    Dec 2023$322.42M+13.4%78.4%8.7%6.6%
    Dec 2022$284.39M+23.4%78.5%15.4%13.9%
    Dec 2021$230.47M+41.0%77.5%14.5%11.9%
    Dec 2020$163.46M+8.8%72.4%4.1%3.6%
    Dec 2019$150.19M+21.2%74.5%7.9%9.4%
    Dec 2018$123.95M+36.8%73.8%5.3%4.0%
    Dec 2017$90.61M+9.9%70.9%-4.0%-2.4%
    Dec 2016$82.43MN/A70.8%-15.4%-14.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income fell 37.2% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$239.44M$313.90M$322.42M$284.39M$230.47M$163.46M$150.19M$123.95M$90.61M$82.43M
    Cost of revenue$57.02M$74.32M$69.76M$61.01M$51.84M$45.10M$38.23M$32.44M$26.33M$24.06M
    Gross profit$182.42M$239.58M$252.65M$223.38M$178.64M$118.36M$111.95M$91.51M$64.28M$58.37M
    Research and development$40.05M$45.32M$40.48M$35.98M$33.86M$31.92M$25.30M$22.03M$20.04M$20.67M
    Operating income-$91.71M-$12.61M$28.10M$43.80M$33.34M$6.77M$11.85M$6.59M-$3.63M-$12.65M
    Net income-$80.45M-$20.21M$21.35M$39.66M$27.51M$5.91M$14.05M$4.97M-$2.14M-$12.13M
    EBITDA-$78.13M-$8.58M$31.76M$46.81M$33.97M$10.68M$15.19M$8.30M$589.00K-$10.06M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$83.41M$93.53M$93.52M$57.80M$94.73M$44.32M$42.59M$48.95M$88.59M$99.00M$77.36M$76.27M
    Gross profit$59.13M$69.73M$68.86M$43.74M$77.88M$32.80M$28.00M$31.65M$68.49M$78.41M$61.03M$60.73M
    Operating income$5.46M$10.10M$7.98M-$22.84M$18.49M-$29.96M-$57.40M-$27.91M$5.68M$11.90M-$2.28M$10.40M
    Net income$5.58M$8.06M$5.21M-$18.31M$8.88M-$16.81M-$54.21M-$34.23M$9.98M$7.38M-$3.34M$7.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $5.87M by $147.28M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$451.68M$509.52M$488.69M$418.82M$345.78M$257.42M$207.52M$167.34M$67.93M$65.48M
    Current assets$311.55M$367.94M$365.27M$311.72M$271.41M$216.42M$174.67M$151.57M$53.89M$49.52M
    Cash and equivalents$153.15M$144.16M$183.04M$86.48M$199.71M$152.45M$119.97M$103.88M$18.52M$14.00M
    Total liabilities$107.49M$112.19M$102.74M$82.71M$87.22M$60.19M$47.64M$34.91M$25.00M$27.57M
    Short-term debt$5.87M$3.94M$4.37M$3.69M$3.41M$1.38M$1.83M$3.78M$5.72M$5.48M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$531.00K$1.34M
    Shareholder equity$344.18M$397.33M$385.95M$336.11M$258.56M$197.22M$159.88M$132.43M$42.94M$37.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$485.16M$475.20M$451.12M$461.62M$456.36M$437.78M$457.36M$509.52M$537.59M$512.75M$492.54M$488.69M
    Total liabilities$109.03M$109.81M$98.75M$117.44M$102.58M$101.21M$107.39M$112.19M$109.47M$103.64M$99.75M$102.74M
    Cash and equivalents$133.61M$148.58M$131.86M$153.15M$176.16M$167.13M$173.11M$144.16M$164.00M$192.78M$224.02M$183.04M
    Shareholder equity$376.13M$365.40M$352.37M$344.18M$353.78M$336.57M$349.97M$397.33M$428.12M$409.10M$392.79M$385.95M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$34.23M$15.72M$14.59M$35.72M$43.96M$20.95M$25.80M$12.77M$2.85M$1.05M
    Capital expenditures$5.82M$23.39M$18.19M$18.11M$13.64M$8.40M$10.10M$2.25M$1.05M$3.21M
    Free cash flow-$40.05M-$7.67M-$3.59M$17.61M$30.32M$12.55M$15.70M$10.52M$1.81M-$2.16M
    Dividends paidN/AN/A$9.67KN/AN/AN/AN/A$5.20M$3.97M$3.98M
    Share repurchases$6.46M$0$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$46.34M-$59.22M$74.35M-$156.38M-$13.64M-$8.40M-$10.18M-$2.25M-$1.05M-$3.21M
    Financing cash flow-$4.55M$5.72M$7.42M$8.30M$17.79M$19.57M$149.00K$74.64M$2.44M$2.95M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$27.32M$19.69M-$21.70M-$3.91M$2.67M-$27.25M-$5.73M$642.00K$3.82M-$10.41M$21.68M$31.97M
    Capital expenditures$935.00K$494.00K$443.00K$1.68M$883.00K$1.79M$1.47M$5.72M$6.23M$6.24M$5.20M$3.09M
    Free cash flow$26.38M$19.20M-$22.14M-$5.59M$1.78M-$29.04M-$7.20M-$5.08M-$2.42M-$16.65M$16.48M$28.88M
    Last 12 quarters

    Frequently Asked Questions About STAA

    What is STAAR Surgical Company's annual revenue?

    STAAR Surgical Company reported revenue of $239.44M for the fiscal year ended Dec 31, 2025.

    How fast is STAAR Surgical Company's revenue growing?

    Revenue was down 23.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.6%.

    Is STAAR Surgical Company profitable?

    No. STAAR Surgical Company reported net income of -$80.45M for the fiscal year ended Dec 31, 2025, with a net margin of -33.6%.

    How much free cash flow does STAA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$34.23M minus capital expenditures of $5.82M produced free cash flow of -$40.05M.

    How much debt does STAAR Surgical Company have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.87M and cash and equivalents of $153.15M.